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Abstract Attenuated polyposis could be defined as a
variant of familial adenomatous polyposis (FAP) in which
synchronous polyps of the large bowel range between 10
and 99. We analysed all cases of attenuated polyposis
observed over the last 30 years with the objectives: (A) to
classify the disease according to different type and pro-
portion of polyps; (B) To ascertain the contribution of APC
and MutYH genes; (C) to discover features which could
arise the suspicion of mutations; (D) To obtain indications
for management and follow-up. 84 individuals in 82 fam-
ilies were studied. Polyps were classified into four groups
as adenoma, hyperplastic, other serrated lesions or others;
APC and MutYH mutations were assessed. Mean age at
diagnosis was 54 ± 14 years in men and 48 ± 13 in
women (P = 0.005). Polyps were more numerous in
women (37 ± 26 vs 29 ± 22). Sixty % of patients under-
went bowel resection, mainly for cancer; the remaining
were managed through endoscopy. A total of 2586 polyps
were detected at diagnostic endoscopy: 2026 (80 %) were
removed and analysed. Adenomas were diagnosed in 1445
(70 %), hyperplastic polyps in 541 (26 %), other serrated
lesions in 61 (2.9 %). Adenomas and hyperplastic lesions
were detected in the majority of patients. In 68 patients
(81 %) in whom studies were executed, APC mutations
were found in 8 and MutYH mutations in 10. Genetic
variants were more frequent in women (12 vs 6,
P = 0.039). Taking into consideration the prevalent
([50 %) histology and presence of mutations, patients
could be subdivided into four groups: (1) APC mutated
polyposis (AFAP), when adenomas were[50 % and APC
mutations detected (no. 8, 10 %); (2) MutYH mutated
polyposis (MAP), adenomas[50 % and biallelic MutYH
mutations (no. 10, 12 %); (1) attenuated polyposis without
detectable mutations, prevalence of adenomas, 48 cases
(57 %); (1) hyperplastic-serrated polyposis, with preva-
lence ([50 %) of hyperplastic/other serrated lesions and no
constitutional mutation (no. 18, 21 %). Aggregation of
tumors, cancer in probands, distribution of polyps and other
clinical characteristics showed no difference among the
four groups. In conclusions, AFAP and MAP, the polyposis
labeled by constitutional mutations, represented about
25 % of all attenuated polyposis. Mutation-associated
cases showed an earlier age of onset of polyps and were
more frequent in the female sex.
Keywords Cancer  Tumor  Polyps  Adenoma 
Hyperplastic  Serrated  FAP  AFAP
Introduction
In a small fraction of cases (\1.0 %) colorectal malig-
nancies develop in patients with familial adenomatous
polyposis (FAP), a rare autosomal dominant condition in
which the colon and rectum are usually carpeted by hun-
dred or thousand polyps of various dimensions [1, 2]. In
most patients the FAP phenotype is associated with con-
stitutional mutation in the APC gene, or, to a lesser
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fraction, in the MutYH gene [3, 4]. Diagnostic criteria,
management and follow-up of FAP patients have been well
characterized, and guidelines were published [5].
Attenuated polyposis (AFAP) is a phenotypic variant
of FAP, in which, according to some authors, the number
of polyps ranges between 10 and 99 [6, 7]. Patients with
AFAP show an attenuated course, with development of
adenomas and carcinoma at a more advanced age than
classical FAP, and a low frequency of extracolonic
manifestations [8, 9]. Moreover, constitutional mutations
in either APC or MutYH genes can be found in no more
than 20–30 % of all cases [6–9]. It is likely that the
widespread use of colonoscopy and the diffusion of col-
orectal cancer screening will induce an increase in the
detection of attenuated polyposis. At variance with FAP,
guidelines on diagnostic criteria, time and type of optimal
treatment, search of lesions in other organs, extent of
surveillance and use of prevention agents remain unde-
fined [10–12].
In addition, other types of attenuated polyposis await a
further definition, and in particular hyperplastic/serrated
polyposis [13–15]. In these patients, polyps tend to be
hyperplastic or ‘‘serrated’’ (saw-teethed), but confusion still
exists, since for some authors serrated polyposis includes
hyperplastic polyposis [16], whereas for others [10] ‘‘serrated
polyps were previously called hyperplastic polyps’’. More-
over, lack of consensus includes not only histologic criteria,
but alsomanagement and follow-up. Finally, in a recent paper
Gill and collaborators showed an almost exponential increase,
in their Pathology Unit, in the diagnosis of sessile serrated
polyposis over a very short period of time: no case diagnosed
in 2009, 134 confirmed cases in 2012 [13].
In the present investigation, through a careful analysis of
all cases of attenuated polyposis presented to our obser-
vation over 30 years, we purposed the following main
objectives: (1) to classify attenuated polyposis mainly on
the basis of the observed histology and to ascertain the
contribution, to the proposed classification, of constitu-
tional mutations in the two cancer-related genes APC and
MutYH; (2) to find out possible clinical and morphological
characteristics which could raise the suspicion of muta-
tions; (3) to discuss clinical management of attenuated
polyposis, with particular attention to time and type of
surgery and to endoscopic follow-up.
Materials and methods
Patients
The study group included 84 patients, all of Italian ancestry
(of 82 different families), with an endoscopic diagnosis of
attenuated polyposis. This was defined as the presence at
endoscopy (the first endoscopic evaluation in the majority
of patients) of a number of synchronous polyps, of any
histological type, ranging from a minimum of 10 to a
maximum of 99 in at least two colorectal segments (IDC-0
Classification) [17]. Patients were usually referred to our
Unit with suspicion of classical FAP, but an evaluation of
clinical charts changed the diagnosis into an attenuated
clinical form (i.e., less than 100 adenomas were present at
the index endoscopy). Only 1 patient (in the APC? group,
Table 2) was less than 25 years old; in this specific case the
diagnosis of classical FAP could not be excluded a priori.
Most subjects were ‘‘single’’ cases, since no other family
member with polyposis was referred by history or detected.
In two families (both with MutYH mutations) two siblings
both showed attenuated polyposis, and were included in the
study. In two families with APC mutations, one of the
parents was affected by ‘‘polyposis’’ by history, so that
only the proband could be included in the study, owing to
lack of detailed information.
In some patients, the evaluation of the exact number of
polyps was rather troublesome, owing to the frequent use,
at endoscopy, of terms such as ‘‘numerous’’, ‘‘many’’, or
‘‘multiple’’. In these cases, endoscopists were recontacted,
and the examinations (medical records and, where avail-
able, videos) re-evaluated in order to establish the most
likely number of polyps at index endoscopy. Despite this,
we remain aware of the difficulty in establishing the correct
number of polyps, at least in some cases.
Families with Peuts–Jeghers syndrome (no. 8), Cowden/
Bannayan disease (no. 2) and Juvenile polyposis (no. 3), all
with less than 10 colorectal polyps, in our experience, were
not included in the study.
Location and histological features
Besides their number at the diagnostic endoscopy, the
distribution of polyps in the various large bowel segments
and their dimensions were carefully recorded. As far as
location was concerned, we subdivided polyps distribution
into three categories: (1) polyps scattered in the ‘‘whole
large bowel’’, (2) polyps predominantly ([50 %) located in
the ‘‘Left colon’’ (Descending, Sigmoid and Rectum) and
(3) polyps predominantly ([50 %) located in the ‘‘Right
colon’’ (from Cecum to Splenic Flexure).
Histologic examination allowed us to classify polyps
into four main categories:
1. ‘‘Adenoma’’, when pseudostratification of nuclei was
evident, together with other classical features of
adenomas, including dysplasia [18];
2. ‘‘Hyperplastic’’, in presence of a single layer of
enterocytes lining the polyp, with no pseudostratifica-
tion and no architectural or cytologic features of sessile
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serrated adenoma (SSP/A) or traditional serrated
adenoma (TSA);
3. ‘‘Serrated’’, in presence of SSP/A or TSA. Since in
many instancies we retrieved a diagnosis of ‘‘serrated
polyp’’ no otherwise specified, and we were not able to
review in our Institutions all 61 polyps diagnosed as
serrated, we used the definition of Serrated lesions
without any further subdivision;
4. ‘‘Other’’ histological types (15 lesions) included a
miscellanea of inflammatory polyps, mixed lesions,
ganglioneuroma and hamartoma (1 polyp).
Molecular biology, APC and MUTYH gene
mutations
Molecular studies were carried out and completed in 68 out
of 84 patients (81 %); of the remaining 16, 4 refused
genetic testing, in 6 the study was not possible for various
reasons, and in 6 molecular definition was under study.
Molecular analysis of the APC gene was executed fol-
lowing standard procedures, as previously described
[19, 20]. Briefly, DNA was extracted either from peripheral
white blood cells or from Epstain–Barr virus-transformed
cell lines that were obtained from probands. DNA was
amplified by PCR, screened by Protein Truncation Test for
exon 18, and directly sequenced for exons 4–18. Negative
tests were sequenced for exon 18. The promoter and the
entire open reading frame were analysed for the presence
of deletions or rearrangements by using the SALSA PO43
APC MLPA Kit from MRC-Holland (Amsterdam, the
Netherlands) according to the manufacturer’s protocol.
MutYH constitutional alterations were studied as already
reported [21, 22]. After DNA extraction and amplification,
the entire open reading frame was sequenced. Amplification
products were obtained from primers located in the flanking
intron regions approximately 50 base pairs from the
respective exons, in order to find out all possible splice-
junction mutations.
Statistical analysis
Clinical characteristics of the investigated patients were
expressed as mean ± standard deviations (SD), or as fre-
quencies. The statistical significance of difference between
groups, based on sex or presence of constitutional muta-
tions, was assessed using Chi-Square, Fisher’s exact,
Kolmogorov–Smirnov or Kruskal–Wallis tests, as
appropriate.
Multiple regression was carried out in order to justify
the variability in the number of observed polyps during
colonoscopy. Multinomial regression analysis was exe-
cuted for evaluating the possible role of clinical and
morphological parameters in predicting the presence of
constitutional mutations. Logistic regression analysis
aimed at identifying patients with major risk to develop
colorectal cancer or to die. All analyses were performed
with STATA 12 software.
Results
Main clinical and morphologic data are summarized in
Table 1. Mean age at diagnosis was 54.0 ± 14 years in
males and 48 ± 13 in females (P = 0.005). Men and
women were almost equally distributed in the study group.
The average number of polyps at the diagnostic endoscopy
was 33 ± 24, range 10–92; polyps were more numerous in
females (37 ± 26 vs 29 ± 22, P = 0.025). In the majority
of patients there was no evidence of malignancy at diag-
nosis (54, 64 %); however colorectal cancer was detected
in 30 (36 %) patients, in most cases at first colonoscopy. It
is rather intriguing that in 5 individuals attenuated poly-
posis developed 1–5 years after intestinal resection for
colorectal carcinoma. In approximately half of patients
polyps were distributed in all colorectal segments; in 20
(24 %), lesions were predominantly located in the Left
colon, in 19 (23 %) in the Right colon. Fifty patients
(60 %) underwent large bowel resections, at diagnosis or
during follow-up. Cancer was the main reason for surgery,
though in 20 patients the approach was chosen because of
polyposis not complicated by malignancy. Thirty-four
(40 %) patients were managed through endoscopic removal
of polyps. Nearly half of the patients (no. 37, 44 %)
underwent colonoscopy because of screening (FOBT,
family history of cancer); in 47 (56 %) symptoms had
developed (the most frequent being rectal bleeding or
abdominal pain). In two cases extracolonic manifestations
(retinal pigmented spots or osteomas) were the first clinical
sign leading to the diagnosis. The large majority of patients
were alive at January 2015; of the 13 patients who had
deceased, 10 died of colorectal cancer and 1 of pancreatic
neoplasm, the remaining two for reasons unrelated to
neoplasms.
A total of 2586 polyps were detected at the diagnostic
endoscopy, of these 2062 (80 %) were removed and anal-
ysed. The histologic diagnosis was adenoma in 1445
(70 %), hyperplastic polyps in 541 (26.2 %), other serrated
lesions in 61 (2.9 %) and other histologic types in 15
(1 %). As shown in Table 1B, adenomas and hyperplastic
polyps were detected in the majority of patients.
In the 68 patients (81 %) in whom molecular analysis
could be executed and completed, 8 showed mutations in
the APC gene (11.7 % of the sample) and 10 additional
subjects in the MutYH gene (14.7 %). Genetic testing was
negative in 50 individuals. Table 2 shows details of the
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mutations, which were more frequent in women (12 vs 6,
P = 0.039 by v2 test).
As shown in Fig. 1, we attempted to classify attenuated
polyposis taking into consideration, besides the number of
polyps, their prevalent histological type and the presence of
constitutional mutations. In 66 cases of 84 (79 %), ade-
noma was the prevalent histology, in the sense that more
than 50 % of the lesions showed adenomatous changes. Of
these 66, 18 (27.3 %) showed mutations and 48 (73 %)
were negative. The group with mutations could be further
subdivided according to the involved gene.
The remaining 18 cases of 84 (21 %) showed predom-
inantly ([50 %) hyperplastic/and other serrated polyps
histology; no mutation in either APC or MutYH could be
detected in this group. More in particular, hyperplastic/and
other serrated lesions were 80 % of the total, adenomas
17 %, other 3 %.
Tentatively, the four resulting groups could be labeled
as follows:
(A) APC mutated familial adenomatous polyposis
(AFAP),
(B) MutYH mutated adenomatous polyposis (MAP),
(C) Attenuated polyposis without detectable mutations
(in the two genes more frequently involved in
polyposis syndromes) and,
(D) Hyperplastic/serrated polyposis.
Table 3 summarizes the main clinical and histologic
features of the four groups of patients. Statistical evaluation
(univariate analysis) showed a significant difference
(P\ 0.001 by Kruskal–Wallis test) in the age of polyp
onset, which was the earliest in the APC mutated group and
the latest for hyperplastic/serrated polyposis. Female sex
was significantly (P = 0.005) more frequent in AFAP,
whereas male sex in attenuated polyposis without muta-
tions. Four of 8 patients with APC mutations and 6 of 10
with MutYH mutations had adenomatous polyps as the
only histological type. None of the patients with hyper-
plastic/other serrated lesions had exclusively polyps of this
histological type, i.e., concomitant adenomas were always
present.
Hyperplastic/Serrated polyposis syndrome has been
defined as the presence of one of the following criteria: (1)
At least 5 hyperplastic/other serrated polyps proximal to
the sigmoid colon, 2 of which of at least 1.0 cm in diam-
eter; (2) any number of hyperplastic/other serrated lesions
occurring proximal to the sigmoid in a subject who has a
first-degree relative with the syndrome; (3) More than 20
hyperplastic/other serrated polyps spread throughout the
colon (23). Of the 18 patients of the present study, 6
showed criterion 1, 14 criterion 3, five more than 1 crite-
rion, no subject displayed features of criterion 2.
By mean of multivariate analysis, we evaluated the
possible association of the most relevant clinical and
Table 1 Main clinical and histological features in the whole study group
Mean age at
diagnosis
Average no.
polyps
Average no.
analyzed polyps
Distribution of polyps
(total/left/right)
Surgery
(yes/no)
Clinical features (A)
Total (no. 84) 51 ± 14 33 ± 24 26 ± 23 45/20/19 50/34
Males (no. 46) 54 ± 14* 29 ± 22# 25 ± 22 26/11/9 27/19
Females (no. 38) 48 ± 13* 37 ± 26# 26 ± 25 19/9/10 23/15
Reasons of colonoscopy
(screening/symptoms)
Patient status
(alive/dead)
Familial aggregation
of tumors (yes/no)
Execution of genetic
testing (yes/no)
Colorectal cancer
(yes/no)
Total (no. 84) 37/47 71/13 59/25 68/16 30/54
Males (no. 46) 20/26 38/8 30/16 37/9 16/30
Females (no. 38) 17/21 33/5 29/9 31/7 14/24
Polyps detected
at endoscopy
Analyzed
polyps
Types of polyps. adenoma/hyperplastic/other
serrated/other (absolute values and
percentage of total)
Type of polyps per patient
Morphologic features (B)
Total (no. 84) 2586 2062 (80 %) 1445/541/61/15 (70, 26.2, 3, 0.7 %) Adenoma 79 of 84
Males (no. 46) 1246 1143 (92 %) 765/347/27/4 (67, 30, 2.4, 0.3 %) Hyperplastic 45 of 84
Females (no. 38) 1340 919 (69 %) 680/194/34/11 (74, 21, 0.4, 0.1 %) Serrated 16 of 84
Hyperplastic ? Serrated 47 of 84
* P = 0.005; # P = 0.025
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morphologic variables (age, sex, presence of mutation,
distribution of polyps, presence or development of cancer,
surgical treatment, endoscopic approach, history of cancer,
symptoms of onset) with: (A) the specific subgroups in
which patients were subdivided (Fig. 1), (B) the develop-
ment of cancer in probands and (C) clinical outcome (dead
or alive). As shown in details in Tables 4, 5 and 6, none of
the investigated variables was associated with any of the
three main end-points. Similarly, no association was
ascertained between clinical variables and total number of
polyps at the index endoscopy.
Discussion
The results of the present investigation can be summarized
as follows:
First, the clinical condition in which 10–99 synchronous
colorectal polyps are detected at endoscopy can tentatively
be classified into four main groups on the basis of histo-
logic features of polyps and presence of constitutional
mutations in either APC or MutYH genes. Second, two of
these groups (AFAP and MAP), which represent nearly
25 % of the total, are labelled by constitutional mutations;
‘‘attenuated polyposis’’ and hyperplastic/serrated polyposis
(Fig. 1) do not show mutations in the above mentioned
genes, and their diagnosis is based on the prevalent
histological type. Third, polyps are usually mixed, in the
sense that adenomatous and hyperplastic/other serrated
lesions tend to cohexist in the majority of these patients, it
is the prevalence ([50 %) of a given histology, or the
presence of germline mutations, which defines each sub-
group, at least with the present approach. Finally, no other
relevant clinical features seem to be specifically associated
with any of the four subgroups, in the sense that (a) a
strong familial aggregation of tumors was present with
approximately the same frequency, (b) cancer occurrence
in probands was in the same order of magnitude (and
colectomy was similarly more frequent than endoscopy as
treatment of choice), and (c) the distribution of polyps in
the large bowel was not different among groups. It is worth
noting that mutation associated cases, especially those with
APC gene alterations, showed an early age of onset of
polyps (Table 3, P\ 0.001). Since genetic cases require a
more intensive clinical research (possible extracolonic
manifestations, including duodenal and ampullary adeno-
mas, desmoid tumors and thyroid nodules) the search of
constitutional mutations is particularly indicated in indi-
viduals with attenuated polyposis with prevalence of ade-
nomas in their third or fourth decade of life. Furthermore,
constitutional mutations were detected more frequently in
the female sex (especially in the APC? group).
Attenuated polyposis can be defined as a variant of FAP, at
least taking into account the phenotypic appearance. As a
Table 2 Constitutional mutations in MUTYH and APC genes detected in 18 individuals
Family MutYH mutation
Allele 1/Allele 2
Family history of polyposis/cancer No. of polyps Age at diagnosis
4 (A) p.(Glu480del)/p.(Glu480del) Yes 50 47
4 (B) p.(Glu480del)/p.(Glu480del) Yes 10 43
5 (A) p.(Tyr179Cys)/p.(Gly396Asp) Yes 24 51
5 (B) p.(Tyr179Cys)/p.(Gly396Asp) Yes 30 50
38 p.(Gln141Argfs*5)/p.(Arg182His) Not 22 32
39 p.(Arg245His)/p.(Arg245His) Not 30 66
47 p.(Tyr179Cys)/p.(Tyr179Cys) Not 30 29
48 p.(Glu480del)/p.(Glu480del) Not 35 34
71 p.(Tyr179Cys)/p.(Tyr179Cys) Not 90 49
61 p.(Tyr179Cys)/p.(Tyr179Cys) Not 11 49
Family APC mutation Family history of polyposis/cancer No. of polyps Age at diagnosis
9 p.(Glu1538Ilefs*5) Not 25 18
19 p.(Lys226Ilefs*66) Yes 30 35
20 p.(Asn1113Serfs*4) Not 20 33
35 g.(113797-?_151992??del) Not 30 44
46 c.(-30434-?_-30079??del) Not 50 27
57 p.(Leu710Serfs*8) Yes 40 34
58 p.(Pro1324G1nfs*91) Yes 20 33
59 p.(Cys110Phefs*12) Not 15 51
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general impression, the condition is increasing in frequency,
presumably as a consequence of a greater awareness among
physicians, but also owing to the widespread diffusion of
colonoscopy and screening procedures. Due to the variability
of clinical and histologic features, the diagnostic criteria have
not been established and the disease can be defined in more or
less complex ways. Thus, while for some authors [11] it can
simply be defined as the presence of 10–20 to 99 polyps in the
large bowel, Nielsen et al. [6] proposed the presence of the
following 2 criteria: (A) at least two first-degree relatives with
10–99 adenomas diagnosed at age [30 years or (B) one
patient with 10–99 adenomas at age[30 and a first-degree
relative with colorectal cancer with a few adenomas, and, in
neither case, family members with more than 100 polyps
before the age of 30 years. And the definition can be made
even more complex if we take into consideration presence or
absence of germline mutations, early onset colorectal cancer
or severe dysplasia, extracolonic manifestations, and a family
history of multiple polyps.
Similarly, besides the histologic classification of
hyperplastic and serrated lesions, diagnosis of hyperplastic/
serrated polyposis remains cumbersome, although most
recent investigations tend to include hyperplastic polyposis
within serrated polyposis [11, 14]. The above mentioned
criteria represent the reference definition for the syndrome
[23]. At somatic level, serrated polyps show an increased
rate of BRAF mutations, CpG island hypermetilation and
DNA microsatellite instability [24–26]; however, these
markers cannot be used with purposes of defining or
classifying the syndrome.
In our opinion, the two reported definitions [6, 23] and
other attempts to classify attenuated polyposis syndromes
[11] miss an important point, which is also the main
message of the present study: in most patients, polyps do
not show a single histological type, but rather a mixture of
adenomatous, hyperplastic and other serrated lesions, and
still other histologies in a few cases only. Consequently,
our attempt to classify attenuated polyposis on the basis of
APC + (8 cases, 44%) (AFAP)
Mut +
(18 cases, 27%)
MutYH + (10 cases, 56%)(MAP)
>50% Adenomas
(66 cases, 79%)
Mut –
(48 cases, 73%)
(Attenuated Polyposis)
Attenuated 
Polyposis
(10-92 polyps)
(n. 84)
>50% Hyperplastic/Serrated Polyposis
(18 cases, 21%) (Mut-)
Prevalent Mutations Involved 
Histological Yes/No Gene
Type
Attenuated Polyposis 48 (57%)
Polyposis APC + (AFAP) 8 (10%)
Polyposis MutYH + (MAP) 10 (12%)
Hyperplastic/Serrated 
Polyposis
18 (21%)
Fig. 1 Tentative classification
of attenuated polyposis
M. P. de Leon et al.
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the prevalent (more than 50 % of the analysed polyps)
histology seems to us rather sound.
In the majority of our patients, no constitutional muta-
tions in either APC or MutYH genes were detected. This
could mean that most of these cases are truly sporadic, and
dependent on some unidentified exogenous factors. How-
ever, other possibilities can be taken into account; for
instance, different genes could be involved. In a large
series of 603 patients selected on the basis of at least one
hamartomatous or hyperplastic/other serrated polyp in the
large bowel—many of them with features of attenuated
polyposis—Ngeow et al. [27] reported that in 77 (13 %)
constitutional mutations in either ENG, PTEN, STK11,
BMPR1A or SMAD4 could be detected. Moreover,
specific constitutional variants in POLE or POLD1 genes
were recently reported among 15 patients selected for the
presence of at least 10 colorectal adenomas in families
with history of colorectal cancer [28]. Clearly, Next Gen-
eration Sequencing could lead to the discovery of several
genes potentially associated with the attenuated polyposis
phenotype. Finally, other possible explanations (for lack of
germline mutations) include APC or MutYH alterations
which are difficult to detect with routine techniques, and
APC mosaicism.
There were two sex-related differences that reached the
statistical significance, and for which we cannot offer any
plausible explanation. The first was the higher (37 vs 29)
average number of polyps in the female sex; the second the
increased rate of mutations (for both genes, but more
evident for APC) again in females. More studies are nee-
ded to further clarify the issue.
A family history of cancer was reported in the majority
of patients (59 of 84, 70 %). As shown in Table 3, this
familiality was present in all four groups, approximately at
the same extent. Although a wide tumor spectrum was
observed, including all commonly occurring malignancies
of humans, colorectal cancer was by far the most fre-
quently referred neoplasm. These findings might suggest
that in some family members intestinal tumors developed
over a background of colorectal polyposis, but a direct
proof of this contention is lacking. As a matter of fact, the
large majority (80 of 84) of investigated individuals were
‘‘single’’ cases, and in no other members of the family
there was evidence of attenuated polyposis.
What about clinical recommendations and management
of attenuated polyposis? Our prolonged observations allow
some prudent suggestions, still awaiting for further studies
in larger and different groups of individuals. Management
is undoubtedly more complex than in classical FAP, a
disease known from the Nineteen century and for which
general guidelines have been accepted [29, 30]. We
strongly recommend for attenuated polyposis of any type
an individualized approach which takes into considerationT
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age of patients, their willingness to undergo colonoscopy,
prevalent histology of the resected polyps, molecular
characterization, presence of a strong family history of
colorectal cancer and distribution of polyps in the large
bowel. For instance, although colectomy or hemicolectomy
were executed in the majority of patients (50 of 84, 60 %),
Table 4 Variables potentially
associated with any of the
specific subgroup of Fig. 1
(AFAP, MAP, attenuated
polyposis, hyperplastic/serrated
polyposis) (multinomial
regression)
Relative risk ratio CI (95 %)
Mut2 Reference category
Hyperplastic polyposis
Age at diagnosis 1.02 0.95 1.09
Sex (M vs F) 2.64 0.61 11.47
Colon DX versus SX 4.20 0.24 72.84
Colon all versus SX 6.73 0.54 83.68
Cancer in families 0.36 0.08 1.75
Colorectal carcinoma (probands) 3.32 0.28 40.12
Symptoms of onset 0.42 0.10 1.79
Surgery 0.22 0.02 2.41
MutYH1
Age at diagnosis 0.94 0.87 1.00
Sex 2.95 0.57 15.42
Colon DX versus SX 2.23 0.09 56.64
Colon all versus SX 6.21 0.50 77.08
Cancer in families 1.12 0.16 7.99
Colorectal carcinoma (probands) 1.17 0.14 10.08
Symptoms of onset 1.21 0.22 6.59
Surgery 2.03 0.23 18.17
APC1
Age at diagnosis 0.79 0.63 1.00
Sex 0.000 0.00 –
Colon DX versus SX 0.00 0.00 –
Colon all versus SX 4.21 0.04 468.36
Cancer in families 0.35 0.01 23.48
Colorectal carcinoma (probands) 0.04 0.00 8.20
Symptoms of onset 1.26 0.03 46.43
Surgery 11.58 0.03 4849.07
Table 5 Variables potentially associated with the development of
Colorectal Cancer in probands (logistic regression)
Odds ratio CI (95 %)
Age at diagnosis 0.98 0.92 1.05
Sex (M vs F) 2.22 0.36 13.63
MutYH? versus Mut- 2.90 0.36 23.28
APC? versus Mut- 0.22 0.01 4.03
Colon DX versus SX 0.50 0.05 5.41
Colon all versus SX 0.27 0.04 2.00
Iperplast versus adenomatous histology 3.94 0.31 49.63
Other versus adenomatous histology 0.000
Cancer in family 0.25 0.05 1.18
Symptoms of onset 2.53 0.38 16.89
Table 6 Variables potentially associated with the clinical outcome
(alive or deceased) (logistic regression)
Odds ratio CI (95 %)
Age at diagnosis 1.15 0.97 1.36
Sex (M vs F) 2.29 0.08 62.84
MutYH? versus Mut- 1.00
APC? versus Mut- 15.21 0.20 1129.36
Colon DX versus SX 0.96 0.04 20.78
Colon all versus SX 0.08 0.00 2.40
Cancer in family 5.12 0.36 71.89
Colorectal carcinoma (probands) 1.07 0.11 10.73
Symptoms of onset 1.18 0.07 19.20
Surgery 2.36 0.06 100.03
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a relevant fraction of individuals with attenuated polyposis
can presumably be managed through endoscopy; this
approach can be considered as appropriate when: (A) the
patient is willing to undergo repeated endoscopies for
many years, and is aware of the possible risk of polyp
degeneration into infiltrating lesions; (B) polyps are rela-
tively few (10–40, approximately) or in any case not so
numerous or large to require immediate surgery; (C) the
endoscopist is confident to obtain a clean colon after each
examination; (D) histology shows low-grade dysplasia in
all lesions. Time interval between endoscopies can also be
individualized, but for most patients ranges between six
and 12 months, although with time larger intervals could
be adequate, at least in some patients. On the other hand
the presence of other criteria favor the execution of sur-
gery, in particular: (1) poor compliance or reluctance of
patients to undergo frequent colonoscopy; (2) presence of
high-degree dysplasia in one or more polyps; (3) presence
of more than 50 polyps, especially when scattered in the
various large bowel segments. Subtotal colectomy with
ileorectal anastomosis appears as the technique of choice
[31], though in cases with polyp localization in one or few
(and contiguous) large bowel segments hemicolectomy or
segmental resections can be taken into consideration.
Finally, according to the suggestion of recent studies
[32, 33] we usually recommend to patients with attenuated
polyposis to reach and maintain their ideal body weight, to
do regular physical exercise at least three times per week,
and to reduce their intake of meat and animal fat.
Rather interestingly, colorectal cancer occurred with
approximately the same frequency in all four categories in
which the study group was subdivided (Fig. 1; Table 3).
This indicates that the risk of cancer is presumably the
same for each type of attenuated polyposis, including
hyperplastic/serrated polyposis [34], and that patients with
constitutional mutations do not seems to carry an additional
risk. It follows that genetic testing is undoubtedly useful,
especially for other family members, and should be rec-
ommended in these patients; however, management of
individual patients seems to be rather independent from the
presence of mutations.
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